Evidence map›Paper›PMID 37965470›Full record

ArticleFrontiers in oncology2023

Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence.

William Lautert-Dutra, Camila M Melo, Luiz P Chaves, Francisco C Souza, Cheryl Crozier, Adam E Sundby, Elizabeth Woroszchuk, Fabiano P Saggioro, Filipe S Avante, Rodolfo B Dos Reis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

William Lautert-DutraDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Camila M MeloDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Luiz P ChavesDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Francisco C SouzaDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Cheryl CrozierDiagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Adam E SundbyDiagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Elizabeth WoroszchukDiagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Fabiano P SaggioroDepartment of Pathology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil.
Filipe S AvanteDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Rodolfo B Dos ReisDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Jeremy A SquireDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Jane BayaniDiagnostic Development, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Universidade de São Paulo · BROntario Institute for Cancer Research · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diverse clinical outcomes of prostate cancer have led to the development of gene signature assays predicting disease progression. Improved prostate cancer progression biomarkers are needed as current RNA biomarker tests have varying success for intermediate prostate cancer. Interest grows in universal gene signatures for invasive carcinoma progression. Early breast and prostate cancers share characteristics, including hormone dependence and BRCA1/2 mutations. Given the similarities in the pathobiology of breast and prostate cancer, we utilized the NanoString BC360 panel, comprising the validated PAM50 classifier and pathway-specific signatures associated with general tumor progression as well as breast cancer-specific classifiers. This retrospective cohort of primary prostate cancers (

Indexed as

biochemical recurrenceCAPRA-Sgene signatureNanoString BC360RNA biomarkersTCGA-PRAD

Identifiers

PMID37965470
PMCPMC10641020
OpenAlexW4387953947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.